Company intelligence / Profile preview
Hillstream BioPharma
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
Overview
Hillstream BioPharma is focused on ferroptosis-inducing therapeutics and bispecific/ADC biologics targeting HER2, HER3, PD-1, and TROP2 in resistant solid tumors. Lead asset HSB-1216 has shown efficacy in pilot clinical study in Germany, with an IND planned for HSB-3215 targeting HER2/HER3. The company is expanding its biologics platform via collaborations for assets against PD-1, TROP2, and MUC1-C.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Bispecific monoclonal antibodyAntibody-drug conjugateSmall moleculeBiologic
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Hillstream BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hillstream BioPharma.